[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR018633A1 - Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo - Google Patents

Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo

Info

Publication number
AR018633A1
AR018633A1 ARP990102715A ARP990102715A AR018633A1 AR 018633 A1 AR018633 A1 AR 018633A1 AR P990102715 A ARP990102715 A AR P990102715A AR P990102715 A ARP990102715 A AR P990102715A AR 018633 A1 AR018633 A1 AR 018633A1
Authority
AR
Argentina
Prior art keywords
radical
compounds
preparation
alkyl
tiepin
Prior art date
Application number
ARP990102715A
Other languages
English (en)
Original Assignee
Gompel Marie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gompel Marie filed Critical Gompel Marie
Publication of AR018633A1 publication Critical patent/AR018633A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D337/00Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02Seven-membered rings
    • C07D337/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Derivados de benzo(B)tiepin-1,1-dioxido, que comprenden compuestos de formula (I), en la cual significan: R1 es metilo, etilo, propilo, butilo;R2 es H, OH, NH2, NH-alquilo C1-6; R3 es un radical de sacárido, radical de disacárido, radical detrisacár ido, radical de tetrasacárido, pudiendoestar el radical de sacárido, el radical de disacárido, el radical de trisacárido o el radical de tetrasacárido mono- o plurisustituido por ungrupo protector de sacárido; R4 es metilo, etilo propilo,butilo; R5 es metilo, etilo propilo, butilo; Z es -(C=O)n-alquilo C0-16, -(C=O)n-alquilo C0-16-NH-,-(C=O)n-alquilo C0-16-O-, -(C=O)n-alquilo C0-16-(C=O)m, un enlace covalente; n es 0 o 1; m es 0 o 1; así como también con sus salesfarmacéuticamentecompatibles y sus derivados fisiologicamente funcionales, así como también procedimientos para su preparacion, medicamentos y empleo de dichos compuestospara la preparacion de medicamentos. Los compuestos son apropiados por ejemplocomo hipolipidémicos.
ARP990102715A 1998-06-10 1999-06-08 Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo AR018633A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19825804A DE19825804C2 (de) 1998-06-10 1998-06-10 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
AR018633A1 true AR018633A1 (es) 2001-11-28

Family

ID=7870440

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990102715A AR018633A1 (es) 1998-06-10 1999-06-08 Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo
ARP990102716A AR018634A1 (es) 1998-06-10 1999-06-08 Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP990102716A AR018634A1 (es) 1998-06-10 1999-06-08 Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.

Country Status (26)

Country Link
US (1) US6387944B1 (es)
EP (2) EP1086092B1 (es)
JP (2) JP4374426B2 (es)
KR (2) KR100681721B1 (es)
CN (2) CN1127497C (es)
AR (2) AR018633A1 (es)
AT (2) ATE227715T1 (es)
AU (2) AU753275B2 (es)
BR (2) BR9912188B1 (es)
CA (2) CA2334775C (es)
CZ (2) CZ297989B6 (es)
DE (3) DE19825804C2 (es)
DK (2) DK1086092T3 (es)
ES (2) ES2182535T3 (es)
HK (2) HK1036799A1 (es)
HU (2) HU229761B1 (es)
ID (2) ID28695A (es)
IL (1) IL140078A (es)
NO (1) NO327075B1 (es)
NZ (1) NZ508681A (es)
PL (2) PL196074B1 (es)
PT (2) PT1086092E (es)
RU (2) RU2215001C2 (es)
TR (2) TR200003634T2 (es)
WO (2) WO1999064410A1 (es)
ZA (2) ZA200007061B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
ATE349425T1 (de) * 2000-12-21 2007-01-15 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
PL366851A1 (en) * 2001-08-22 2005-02-07 Aventis Pharma Deutschland Gmbh Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
JP3616635B2 (ja) 2001-09-08 2005-02-02 アストラゼネカ アクチボラグ 高脂質血症の治療のための回腸胆汁酸運搬(ibat)阻害活性を持つベンゾチアゼピン及びベンゾチアジアゼピン誘導体
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
US20040138145A1 (en) * 2002-12-12 2004-07-15 Aventis Pharma S.A. Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
DE102006053636B4 (de) * 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
DE102006053635B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20100221513A1 (en) * 2008-09-05 2010-09-02 Wisconsin Alumni Research Foundation Self sintering transparent nanoporous thin-films for use in self-cleaning, anti-fogging, anti-corrosion, anti-erosion electronic and optical applications
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP3400944B1 (en) 2010-11-08 2020-07-15 Albireo AB Ibat inhibitors for the treatment of liver diseases
AU2011326872C1 (en) 2010-11-08 2015-02-19 Albireo Ab A pharmaceutical combination comprising an IBAT inhibitor and a bile acid binder
EA201891154A1 (ru) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
WO2014144485A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
RU2015139731A (ru) 2013-03-15 2017-04-20 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециркуляции желчных кислот для лечения первичного склерозирующего холангита и воспалительного заболевания кишечника
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja) 2014-06-25 2020-09-02 Eaファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
JP6954926B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
ES2874546T3 (es) 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3100113A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MX2020013774A (es) 2018-06-20 2021-03-02 Albireo Ab Modificaciones de cristales de odevixibat.
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
HUE060905T2 (hu) 2019-02-06 2023-04-28 Albireo Ab Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként
CN118834175A (zh) 2019-02-06 2024-10-25 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
US20220160726A1 (en) 2019-02-12 2022-05-26 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
TW202134218A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
CN114761018A (zh) 2019-12-04 2022-07-15 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
IL293379A (en) 2019-12-04 2022-07-01 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
EP4188541A1 (en) 2020-08-03 2023-06-07 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
WO2022117778A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2024121434A1 (en) 2022-12-09 2024-06-13 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
ES2155136T3 (es) * 1994-09-13 2001-05-01 Monsanto Co Nuevas benzotiepinas que tienen actividad como inhibidores del transporte de acido biliar iliaco y la captacion de taurocolato.
JP2001526627A (ja) * 1996-03-11 2001-12-18 ジー.ディー.サール アンド カンパニー 回腸胆汁酸輸送及びタウロコール酸塩吸収の阻害剤としての活性を有する新規ベンゾチエピン類
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
EP1104416A2 (en) * 1998-08-20 2001-06-06 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents

Also Published As

Publication number Publication date
DK1086113T3 (da) 2004-05-24
HK1039490A1 (en) 2002-04-26
CZ20004592A3 (cs) 2001-04-11
WO1999064409A3 (de) 2000-03-02
PT1086092E (pt) 2003-03-31
CN1305487A (zh) 2001-07-25
JP2002517491A (ja) 2002-06-18
RU2220141C2 (ru) 2003-12-27
CN1305469A (zh) 2001-07-25
ID28695A (id) 2001-06-28
HUP0102554A1 (hu) 2001-10-28
DE59903411D1 (de) 2002-12-19
CZ20004591A3 (cs) 2001-04-11
EP1086092A1 (de) 2001-03-28
CA2334775C (en) 2009-10-13
AU4503199A (en) 1999-12-30
AR018634A1 (es) 2001-11-28
CA2334773C (en) 2009-05-26
IL140078A (en) 2004-08-31
ES2182535T3 (es) 2003-03-01
DE19825804C2 (de) 2000-08-24
HUP0102256A1 (hu) 2001-12-28
KR20010052701A (ko) 2001-06-25
EP1086113A2 (de) 2001-03-28
KR20010052682A (ko) 2001-06-25
HU229761B1 (hu) 2014-06-30
JP3374129B2 (ja) 2003-02-04
ATE259372T1 (de) 2004-02-15
KR100681721B1 (ko) 2007-02-15
HK1036799A1 (en) 2002-01-18
CN1152039C (zh) 2004-06-02
NO20006251D0 (no) 2000-12-08
PL344827A1 (en) 2001-11-19
PL196074B1 (pl) 2007-12-31
BR9912188A (pt) 2001-04-10
JP4374426B2 (ja) 2009-12-02
PL196057B1 (pl) 2007-11-30
PT1086113E (pt) 2004-06-30
ZA200007060B (en) 2001-07-18
DK1086092T3 (da) 2003-03-10
CZ297989B6 (cs) 2007-05-16
NZ508681A (en) 2002-06-28
AU752633B2 (en) 2002-09-26
RU2215001C2 (ru) 2003-10-27
ATE227715T1 (de) 2002-11-15
EP1086092B1 (de) 2002-11-13
NO20006251L (no) 2001-02-07
JP2002517490A (ja) 2002-06-18
HUP0102554A3 (en) 2002-12-28
NO327075B1 (no) 2009-04-20
BR9911123A (pt) 2006-01-03
HUP0102256A3 (en) 2002-04-29
EP1086113B1 (de) 2004-02-11
CN1127497C (zh) 2003-11-12
CA2334773A1 (en) 1999-12-16
TR200003634T2 (tr) 2001-06-21
BR9912188B1 (pt) 2010-12-14
KR100562184B1 (ko) 2006-03-20
PL345901A1 (en) 2002-01-14
AU753275B2 (en) 2002-10-10
DE59908522D1 (de) 2004-03-18
US6387944B1 (en) 2002-05-14
AU4501999A (en) 1999-12-30
WO1999064409A2 (de) 1999-12-16
ZA200007061B (en) 2001-07-18
ES2215387T3 (es) 2004-10-01
ID26876A (id) 2001-02-15
DE19825804A1 (de) 1999-12-16
TR200003632T2 (tr) 2001-04-20
BR9911123B1 (pt) 2010-12-14
WO1999064410A1 (de) 1999-12-16
IL140078A0 (en) 2002-02-10
CZ297925B6 (cs) 2007-05-02
CA2334775A1 (en) 1999-12-16
HU228570B1 (en) 2013-04-29

Similar Documents

Publication Publication Date Title
AR018633A1 (es) Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo
ES2065904T3 (es) Hidroxietil-celulosa hidrofobamente modificada con carboximetilo (cmhmec) y uso de cmhmhec en composiciones de revestimiento protector.
RS49850B (sr) Derivati 1,4-benzotiazepin-1,1-dioksida supstituisani radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
HUP0300393A2 (hu) C-aril glükozid SGLT2 inhibitorok és alkalmazásuk, valamint ezeket tartalmazó gyógyszerkészítmények
PL358428A1 (en) 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group
AR071959A1 (es) Derivado de benceno o tiofeno y su uso como inhibidor de vap-1
BR9916772A (pt) Quinolinacarboxamidas como agentes antivirais
BR9707606B1 (pt) ácidos 8-ciano-1-ciclopropil-7-(2,8-diazabiciclo(4.3.0) nonan-8-il)-6-flúor-1,4-diidro-4-oxo-3-quinolinocarbo xìlicos, bem como medicamentos que os compreendem.
TR200100609T1 (tr) Sıvı çekici formunda dengelenmiş eczacılıkla ilgili bileşik
PE20020228A1 (es) Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa
ES2176698T3 (es) Nuevos derivados de la eritromicina, su procedimiento de preparacion y su aplicacion como medicamentos.
BRPI0413353A (pt) composição farmacêutica contendo droga solúvel em água
NO20014529L (no) Tetrahydropyranderivater og deres anvendelse som terapautiske midler
ES2126966T3 (es) Proceso para la impregnacion hidrofuga de yeso.
AR018014A1 (es) Compuestos derivados de 3,6-hemicetales de la clase de los 9a-azalidos, un procedimiento para prepararlos y composiciones farmaceuticas que los comprenden.
AR023807A1 (es) Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco
AR007997A1 (es) Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende.
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
ES2032335T3 (es) Nuevos derivados flavonoides 2-piperazinil-2-oxo-etilen sustituidos, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
ES2026555T3 (es) Derivados del piridoinol; su aplicacion a titulo de medicamentos y las composiciones que los contienen.
PE20010493A1 (es) Proceso para la preparacion de un analogo de carbonato de metilo del carbono 4, del paclitaxel
KR900014385A (ko) 제약학적 치료
BR0213403A (pt) Derivados de hidroxialquila indolocarbazol, o respectivo processo de preparo, e as composições farmacêuticas que os contêm
ES2174323T3 (es) Nuevos derivados de la eritromicina, su procedimiento de preparacion y su aplicacion como medicamentos.
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina

Legal Events

Date Code Title Description
FG Grant, registration